Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April

Executive Summary

FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23

You may also be interested in...



GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced

GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market

GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced

GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market

Rx Safety Cmte.’s Holmboe Sees Communication As Key To Risk Management

Yale University's Eric Holmboe, MD, will be taking his second look at risk-management proposals for GlaxoSmithKline's Lotronex during the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee

Related Content

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel